July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more
Despite multibillion dollar impairment, Sanofi beats on 2Q19 earnings
Sanofi (Euronext:SAN; NASDAQ:SNY) reported 2Q19 sales of €496 million from dermatitis and asthma drug Dupixent dupilumab, beating the Street's estimate of €411 million. The pharma also took a €1.8 billion ($2 billion) impairment mainly related to sales of hemophilia drug Eloctate efmoroctocog alfa, which brought in €171 million in sales, below analyst expectations of €180 million. Sanofi reported EPS of €1.31 on revenues of €8.63 billion, ahead of consensus estimates of €1.26 and €8.43 billion, respectively.
Twist unveils long oligos for drug development
Twist Bioscience Corp. (NASDAQ:TWST) launched its commercial portfolio of long oligonucleotides, which can reach up to 300 bases. The company said the oligos can be used for drug discovery and development and DNA data storage, as well as for CRISPR gene editing and protein engineering...